No abstract

No abstract

The incidence of pharyngeal gonorrhea and rectal chlamydia in MSM who visited the Columbia Health Service was similar to rates of asymptomatic nonurethral gonorrhea and chlamydia in studies conducted in the MSM population in non-university settings. This suggests that, following the Centers for Disease Control and Prevention guidelines, 3-site testing for MSM seen at the Columbia clinic is indicated. NAAT is more sensitive than culture for nonurethral gonorrhea and chlamydia.

No abstract

Dr. Saag, the question that I think is probably one of the most frequently asked. What do you start treatment with? Suppose a new patient, with no retroviral history, comes to you with a CD4 count between 400 and 500 and a viral load of 10,000 to 15,000 copies. DR. SAAG: There is more to consider in initial therapies than just retroviral load and CD4 count. It is also about who are they as a person, how motivated are they, and are they ready to start therapy? MR. FROST (MODERATOR): Let's say, as a patient, I am ready to start. I am ready to go. DR. SAAG: Alright. Then in talking to you, I would find out whether you want to be hy-peraggressive or whether you want to be more conservative in treatment approach. MR. FROST (MODERATOR): "Gosh, I do now know, Doc. You tell me." DR. SAAG: In that case, with a CD4 count of 400 and a viral load of 15,000,1 would person